

Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

KN Stevens¹, M Garcia-Closas², Z Fredericksen¹, M Kosel¹, VS Pankratz¹, JL Hopper³, GS Dite³, C Apicella³, MC Southey⁴, MK Schmidt⁵, A Broeks⁵, LJ Van 't Veer⁵, RAEM Tollenaar⁶, PA Fasching^{7,8}, MW Beckmann⁸, A Hein⁸, AB Ekici⁹, N Johnson¹⁰, J Peto¹¹, I dos Santos Silva¹¹, L Gibson¹¹, E Sawyer¹², I Tomlinson¹³, MJ Kerin¹⁴, S Chanock¹⁵, J Lissowska¹⁶, DJ Hunter¹⁷, RN Hoover¹⁵, GD Thomas¹⁵, RL Milne¹⁸, JI Arias Pérez¹⁹, A González-Neira²⁰, J Benítez²¹, B Burwinkel^{22,23}, A Meindl²⁴, RK Schmutzler²⁵, CR Bartrar²⁶, U Hamann²⁷, YD Ko²⁸, T Brüning²⁹, J Chang-Claude³⁰, R Hein³⁰, S Wang-Gohrke³¹, T Dörk³², P Schürmann³², M Bremer³³, P Hillemanns³⁴, N Bogdanova³³, JV Zalutsky³⁴, YI Rogov³⁴, N Antonenkova³⁴, A Lindblom³⁵, S Margolin³⁶, A Mannermaa³⁷, V Kataja³⁸, V-M Kosma³⁷, J Hartikainen³⁷, G Chenevix-Trench³⁹, X Chen³⁹, P Peterlongo⁴⁰, B Bonanni⁴¹, L Bernard⁴², S Manoukian⁴³, X Wang¹, J Cerhan¹, CM Vachon¹, J Olson¹, GG Giles^{44,45}, L Baglietto^{44,45}, CA McLean⁴⁶, G Severi^{44,45}, EM John⁴⁷, A Miron⁴⁸, R Winqvist⁴⁹, K Pylkäs⁴⁹, A Jukkola-Vuorinen⁵⁰, M Grip⁵¹, I Andralis^{52,53,54}, JA Knight^{55,56}, G Glendon⁵², AM Mulligan^{57,58}, A Cox⁵⁹, IW Brock⁵⁹, G Elliott⁶⁰, SS Cross⁶¹, PP Pharoah⁶², AM Dunning⁶³, KA Pooley⁶³, MK Humphreys⁶⁴, J Wang⁶⁴, D Kang⁶⁵, K-Y Yoo⁶⁵, D-Y Noh⁶⁵, S Sangrajrang⁶⁶, V Gabrielou⁶⁷, P Brennan⁶⁷, J McKay⁶⁷, H Anton-Culver⁶⁸, A Ziogas⁶⁸, FJ Couch^{*,69} and DF Easton^{63,64} the GENICA Network, kConFab Investigators, Australian Ovarian Cancer Study Group⁷⁰

¹Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; ²Sections of Epidemiology and Genetics, Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, 123 Old Brompton Road, London SW7 3RP, UK; ³Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Victoria 3010, Australia; ⁴Department of Pathology, The University of Melbourne, Victoria 3010, Australia; ⁵The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; ⁶Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands; ⁷Division of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; ⁸Department of Gynecology and Obstetrics, University Breast Center Franconia, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Schloßplatz 4, 91054 Erlangen, Germany; ⁹Institute of Human Genetics, Friedrich-Alexander University Erlangen-Nuremberg, Schloßplatz 4, 91054 Erlangen, Germany; ¹⁰Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK; ¹¹Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; ¹²National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London SE19RT, UK; ¹³Oxford Biomedical Research Centre, Molecular and Population Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; ¹⁴NUIG Department of Surgery, Clinical Science Institute, University Hospital Galway, Galway O91 524 411, Ireland; ¹⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, MSC 7242, Bethesda, MD 20892-7335, USA; ¹⁶Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Memorial Cancer Center, Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland; ¹⁷Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA; ¹⁸Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; ¹⁹Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Av. Doctores Fernández Vega 107, Oviedo 33012, Spain; ²⁰Human Genterotyping Unit (CeGen), Spanish National Cancer Research Centre (CNIO), Madrid, Spain; ²¹Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Calle Melchor Fernández Almagro 3, Madrid 28029, Spain; ²²Department of Obstetrics and Gynecology, University Hospital Heidelberg, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; ²³Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; ²⁴Department of Gynaecology and Obstetrics, Technical University of Munich, Arcisstraße 21, 80333 Munich, Germany; ²⁵Division of Molecular Gynecology, Department of Gynaecology and Obstetrics, Center of Molecular Medicine Cologne (CMMC), University Hospital of Cologne, 50931 Cologne, Germany; ²⁶Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany; ²⁷Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; ²⁸Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Betriebsstätte Johanniter Krankenhaus, Johanniterstraße 3-5; 53113 Bonn, Germany; ²⁹Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Burkle-de-la-Camp-Platz 1, 44789 Bochum, Germany; ³⁰Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; ³¹Department of Obstetrics and Gynecology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany; ³²Hannover Medical School, Gynaecology Research Unit, 30625 Hannover, Germany; ³³Hannover Medical School, Clinics of Radiation Oncology, 30625 Hannover, Germany; ³⁴Hannover Medical School, Clinics of Obstetrics and Gynaecology, 30625 Hannover, Germany; ³⁵Department of Molecular Medicine and Surgery, Karolinska Institutet, S17176 Stockholm, Sweden; ³⁶Department of Oncology Pathology, Karolinska Institutet, S17176 Stockholm, Sweden; ³⁷Institute of Clinical Medicine, Department of Pathology, University of Eastern Finland and Kuopio University Hospital, Biocenter Kuopio, FI-70211 Kuopio, Finland; ³⁸Institute of Clinical Medicine, Department of Oncology, University of Eastern Finland, Kuopio University Hospital, FI-70211 Kuopio, Finland; ³⁹Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4029,

*Correspondence: Dr FJ Couch; E-mail: couch.fergus@mayo.edu

⁷⁰ See Appendix.

Australia; ⁴⁰Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT) and IFOM, Fondazione Istituto FIRC di Oncologia Molecolare; via Adamello, 16 - 20139 Milano, Italy; ⁴¹Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, via Ripamonti 435, 20141 Milano, Italy; ⁴²Department of Experimental Oncology, Istituto Europeo di Oncologia and Consortium for Genomics Technology (Cogentech); via Adamello, 16 - 20139 Milano, Italy; ⁴³Unit of Medical Genetics, Department of Preventive and Preventive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), via Venezian 1 - 20133 Milano, Italy; ⁴⁴Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton VIC 3053, Australia; ⁴⁵Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Level 4, 207 Bouverie Street, Victoria 3010, Australia; ⁴⁶Department of Anatomical Pathology, The Alfred Hospital, Commercial Road, Prahran VIC 3181, Australia; ⁴⁷Department of Epidemiology, Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538, USA; ⁴⁸Department of Surgery, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, USA; ⁴⁹Laboratory of Cancer Genetics, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, Aapistie 5 A, 90220 Oulu, Finland; ⁵⁰Department of Oncology, University of Oulu, Oulu University Hospital, Aapistie 5 A, 90220 Oulu, Finland; ⁵¹Department of Surgery, University of Oulu, Oulu University Hospital, Aapistie 5 A, 90220 Oulu, Finland; ⁵²Ontario Cancer Genetics Network, Cancer Care Ontario, 620 University Avenue, Toronto, ON M5G 2C1 ON, Canada; ⁵³Fred A. Litwin Center for Cancer Genetics, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5, ON Canada; ⁵⁴Department of Molecular Genetics, University of Toronto, 105 George Street, Toronto, ON M5A 2N4 ON, Canada; ⁵⁵Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, ON M5G 1X5 ON, Canada; ⁵⁶Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, 105 George Street, Toronto, ON M5A 2N4 ON, Canada; ⁵⁷Department of Laboratory Medicine and Pathobiology, University of Toronto, 105 George Street, Toronto, ON M5A 2N4 ON, Canada; ⁵⁸Department of Laboratory Medicine and Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, 30 Bond Street, Toronto, ON M5B 1W8 ON, Canada; ⁵⁹Faculty of Medicine, Dentistry and Health, University of Sheffield, Beech Hill Road, Sheffield S102RX, UK; ⁶⁰Medical Genetics Research Group, Faculty of Medicine and Human Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK; ⁶¹Department of Neuroscience, Faculty of Medicine, Dentistry and Health, University of Sheffield, Beech Hill Road, Sheffield S102RX, UK; ⁶²United Kingdom Department of Oncology and Department of Public Health and Primary Care University of Cambridge, Cambridge, UK; ⁶³Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK; ⁶⁴Centre for Cancer Genetic Epidemiology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK; ⁶⁵Seoul National University College of Medicine, Yongon 103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea; ⁶⁶National Cancer Institute, Rama 6 Road, 10400 Bangkok, Thailand; ⁶⁷International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France; ⁶⁸Department of Epidemiology, School of Medicine, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA; ⁶⁹Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (*PIK3CA*) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer.

METHODS: A single-nucleotide polymorphism from the *PIK3CA* locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30949 cases and 29788 controls from the Breast Cancer Association Consortium (BCAC).

RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR) = 0.97, 95% confidence interval (CI) 0.95–0.99, $P = 4.6 \times 10^{-3}$), but did not reach significance in the BCAC replication study alone (OR = 0.98, 95% CI 0.96–1.01, $P = 0.139$).

CONCLUSION: Common germline variation in *PIK3CA* does not have a strong influence on the risk of breast cancer
British Journal of Cancer (2011) **105**, 1934–1939. doi:10.1038/bjc.2011.448 www.bjcancer.com

Published online 27 October 2011

© 2011 Cancer Research UK

Keywords: genetic susceptibility; neoplasms; association study

Phosphatidylinositol-3 kinases (PI3Ks) constitute a lipid kinase family integral to signalling pathways that regulate many cancer-related processes, including cell proliferation, adhesion, apoptosis, survival and motility (Fruman *et al*, 1998; Cantley, 2002). Alteration of PI3K family members, such as amplification of the phosphoinositide-3-kinase catalytic subunit alpha (*PIK3CA*) oncogene on chromosome 3q26 that encodes the p110 α catalytic subunit of PI3K, are commonly observed in human cancers. Amplification and overexpression of *PIK3CA* results in increased production of the phosphatidylinositol-3,4,5-triphosphate second messenger, hyperactivation of the PI3K/AKT pathway, and stimulation of cellular transformation and tumour progression (Shayesteh *et al*, 1999; Ma *et al*, 2000; Fresno Vara *et al*, 2004; Saal *et al*, 2005; Samuels and Ericson, 2006). Somatic mutations in *PIK3CA* are also common in colon (18–32%), gastric (4–25%), endometrial (36%), liver (36%), brain (27%) and breast (18–40%)

tumours (Bachman *et al*, 2004; Campbell *et al*, 2004; Samuels *et al*, 2004; Karakas *et al*, 2006; Ligresti *et al*, 2009). Functional analyses have shown that many of these mutations activate PIK3CA enzymatic activity and stimulate downstream AKT signalling, promoting growth factor-independent growth and metastasis (Samuels *et al*, 2004; Samuels and Ericson, 2006).

In breast tumours, *PIK3CA* mutations have been consistently associated with ER-positive and human epidermal growth factor receptor-2 (HER2)-positive tumour status (Saal *et al*, 2005; Li *et al*, 2006; Perez-Tenorio *et al*, 2007; Stemke-Hale *et al*, 2008) (Saal *et al*, 2005; Perez-Tenorio *et al*, 2007). The correlation between these mutations and breast cancer prognosis is less clear, with several studies reporting associations between *PIK3CA* mutations and lymph node metastasis and worse overall and breast cancer-specific survival (Saal *et al*, 2005; Li *et al*, 2006; Lai *et al*, 2008; Aleskandarany *et al*, 2010), whereas other studies have

reported associations with longer survival particularly among patients with ER-positive, HER2-negative tumours (Perez-Tenorio *et al*, 2007; Kalinsky *et al*, 2009; Loi *et al*, 2010).

Although the pathological and clinical significance of *PIK3CA* somatic mutations has been well studied, the contribution of inherited variation in this important oncogene to risk of breast cancer is unknown. Here we investigated the influence of germline variation in *PIK3CA* on breast cancer risk.

MATERIALS AND METHODS

Mayo clinic breast cancer study

The details of the Mayo Clinic Breast Cancer case-control Study (MCBCS) have been described previously (Wang *et al*, 2008). Briefly, cases were comprised of Caucasian women with invasive breast cancer diagnosed within 6 months of ascertainment with no prior history of cancer. Controls were comprised of Caucasian women visiting the Mayo Clinic for general medical exams in the Department of Internal Medicine with no prior history of cancer. Participants were recruited under an Institutional Review Board approved protocol. A total of 798 cases and 843 controls were utilised for stage 1 genotyping (Table 1).

Replication studies

The Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer case-control study and 26 case-control studies from Breast Cancer Association Consortium (BCAC) contributed data to these analyses (described in Supplementary Table 1). Stage 1 of the CGEMS GWAS included 1145 cases and 1142 controls of self-reported white European ancestry (Thomas *et al*, 2009), whereas the combined Stage 1 and 2 of CGEMS included a total of 5436 cases and 5280 controls (Table 1). The BCAC replication was comprised of 24 studies of women of primarily European descent (Supplementary Table 1), 1702 additional samples from MCBCS and two studies (SEBCS and TBCS) of women from Southeast Asia (Table 1). Final combined analyses included 35 991 breast cancer cases and 35 153 controls of white European ancestry, as well as 2183 breast cancer cases and 1469 controls of Asian ancestry. Study participants were recruited under protocols approved by the institutional review board at each institution and all subjects provided written informed consent.

Genotyping

Four haplotype-tagging single-nucleotide polymorphisms (SNPs) within *PIK3CA* (rs13320527, rs3729692, rs1607237, rs9838117) were selected ($r^2 > 0.80$ in European-American genotype data from HapMap release 21). A total of 1741 Mayo Clinic samples (798 cases, 843 controls and 100 duplicates) were genotyped on custom oligo pool assays at Illumina Corporation (San Diego, CA, USA) using the Illumina GoldenGate assay. All SNPs had genotype call rates $> 95\%$. Concordance between duplicate samples was 100%. Genotyping of rs1607237 in CGEMS and BCAC was performed using a TaqMan allelic discrimination assay or the Sequenom platform (Sequenom, San Diego, CA, USA) via standard protocols. Genotyping concordance was verified with internal duplicates and overall data quality was ensured using independent genotyping of 96 CEU samples by each genotyping center (Garcia-Closas *et al*, 2008). All studies met the specified criteria for call rate ($> 95\%$).

Pathology and tumour markers

The collection of pathology and tumour marker information for BCAC has been described previously (Yang *et al*, 2011). Pathology data were also available for 900 CGEMS subjects. Briefly, studies provided information on histopathological subtype, grade of

Table 1 Studies contributing to evaluation of associations between rs1607237 and breast cancer risk

Study ^a	Country	Cases n (%)	Controls n (%)
ABCFS	Australia	1199 (3.1)	438 (1.2)
ABCS	The Netherlands	1465 (3.8)	548 (1.5)
BBCC	Germany	1060 (2.8)	994 (2.7)
BBCS	UK	1153 (3.0)	831 (2.3)
BIGGS	Ireland	1060 (2.8)	900 (2.5)
CGEMS ^b	USA	5436 (14.2)	5280 (14.4)
CNIO-BCS	Spain	752 (2.0)	823 (2.2)
GC-HBOC	Germany	864 (2.3)	1224 (3.3)
GENICA	Germany	1013 (2.7)	1012 (2.8)
GESBC	Germany	563 (1.5)	564 (1.5)
HABCS	Germany	1046 (2.7)	998 (2.7)
HMBCS	Belarus	1760 (4.6)	1015 (2.8)
KARBAC	Sweden	812 (2.1)	863 (2.4)
kConFab/AOCS	Australia/New Zealand	566 (1.5)	899 (2.5)
KBCP	Finland	485 (1.3)	427 (1.2)
MARIE	Germany	2754 (7.2)	5302 (14.5)
MBCSG	Italy	739 (1.9)	1231 (3.4)
MCBCS ^c	USA	1789 (4.7)	1554 (4.2)
MCCS	Australia	679 (1.8)	751 (2.1)
NC-BCFR	USA	388 (1.0)	154 (0.4)
OBBCS	Finland	544 (1.4)	509 (1.4)
OFBCR	Canada	1170 (3.1)	329 (0.9)
SBCS	UK	1217 (3.2)	1201 (3.3)
SEARCH	UK	6520 (17.1)	6779 (18.5)
SEBCS ^d	Korea	1732 (4.5)	1178 (3.2)
TBCS ^d	Thailand	451 (1.2)	291 (0.8)
UCIBCS	USA	957 (2.5)	527 (1.4)
Total		38 174 (100)	36 622 (100)

^aSee Supplementary Table 1 for definition of study acronyms. ^bStage 2: Cancer Genetic Markers of Susceptibility study. ^cIncludes Stage 1: Mayo Clinic Breast Cancer Study. ^dAsian case-control studies.

differentiation, tumour size, nodal involvement and stage at diagnosis of breast tumours. All studies except BBCS, GC-HBOC and HMBCS provided data on ER and progesterone receptor (PR) status of tumours, and 12 studies provided data on HER2 (Supplementary Table 2). ER/PR status was most commonly defined using data from medical records. Oestrogen receptor and PR negative status was defined as $< 10\%$ of the tumour cells stained. Human epidermal growth factor receptor-2-negative status was typically defined as a score of 0 or 1+ on a HER2 immunohistochemistry (IHC) scale of 0–3+.

Statistical methods

Evidence of departure from Hardy-Weinberg equilibrium (HWE) was assessed in controls using a goodness of fit test and none was observed (HWE $P \geq 0.001$). Single-nucleotide polymorphism associations were tested using unconditional logistic regression adjusting for age and state of residence in a log-additive model. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) separately for heterozygotes and rare homozygotes. The association between rs1607237 and breast cancer risk in stage 1 of the CGEMS GWAS was evaluated as previously described (Thomas *et al*, 2009). Associations with breast cancer risk in the BCAC studies and the combined BCAC, MCBCS and CGEMS studies were evaluated using unconditional logistic regression adjusting for study center. A likelihood ratio test of heterogeneity by age groups was not significant ($P = 0.10$), and further adjustment for age did not change the results. Analyses of pathology-specific subsets of cases were conducted using polytomous regression with controls as the reference outcome, adjusting for study site.

Table 2 Associations between rs1607237 and breast cancer in MCBCS, CGEMS and BCAC

	Cases	Controls	Log-additive model		2-d.f. model	
			OR (95% CI)	P-value	Heterozygous OR (95% CI)	Homozygous OR (95% CI)
Stage 1: MCBCS	798	843	0.85 (0.73–0.98)	0.023	0.75 (0.60–0.93)	0.76 (0.57–1.01)
Stage 2: CGEMS	5436	5280	0.92 (0.88–0.98)	0.0050	1.00 (0.92–1.09)	0.82 (0.73–0.92)
Stage 3: BCAC	28 766	28 319	0.98 (0.96–1.01)	0.139	0.96 (0.93–1.00)	0.97 (0.92–1.02)
Combined analysis	35 991	35 153	0.97 (0.95–0.99)	0.0046	0.97 (0.93–1.00)	0.94 (0.90–0.98)
Invasive	33 660	34 988	0.97 (0.95–0.99)	0.012	0.97 (0.94–1.00)	0.95 (0.90–0.99)
DCIS	1 159	16 889	0.93 (0.85–1.02)	0.12	0.98 (0.85–1.12)	0.84 (0.70–1.02)

Abbreviations: BCAC = Breast Cancer Association Consortium; CGEMS = Cancer Genetic Markers of Susceptibility; CI = confidence interval; DCIS = ductal carcinoma *in situ*; MCBCS = Mayo Clinic breast cancer case-control study; OR = odds ratio.

RESULTS

Of four *PIK3CA* haplotype-tagging SNPs, rs1607237 was significantly associated with risk of breast cancer in MCBCS (OR = 0.85, 95% CI 0.73–0.98, $P = 0.023$; Table 2, Supplementary Figure 1). Next we evaluated associations between rs1607237 and breast cancer risk in 1145 cases and 1142 controls genotyped in stage 1 of the CGEMS breast cancer GWAS (Thomas *et al*, 2009). Rs1607237 was significantly associated with breast cancer risk (heterozygous OR = 1.12, homozygous OR = 0.79, score $P = 0.017$). To provide a more stable estimate of risk in this population, 8429 additional CGEMS subjects were genotyped for rs1607237. In all 5436 cases and 5280 controls from stage 1 and 2 of CGEMS, rs1607237 was strongly associated with a decrease in breast cancer risk (OR = 0.92, 95% CI 0.88–0.98, $P = 0.0050$; Table 2).

This finding provided the rationale for further evaluation of this SNP in 23 BCAC studies involving women of European ancestry (28 766 cases, 28 319 controls), and two BCAC studies of Asian women (2183 cases, 1469 controls; Table 1). Rs1607237 was not significantly associated with breast cancer risk in the 23 BCAC studies of women of European ancestry (OR = 0.98, 95% CI 0.96–1.01, $P = 0.139$) or in the two Asian BCAC studies (OR = 1.05, 95% CI 0.94–1.16, $P = 0.39$; Table 2). However, when combining all genotype data from the three stages of this study (MCBCS, CGEMS and BCAC; Supplementary Table 3), rs1607237 was significantly associated with risk of breast cancer (OR = 0.97, 95% CI 0.95–0.99, $P = 9.5 \times 10^{-3}$). Similarly, a significant association was observed when considering only women of European ancestry in the combined analysis (OR = 0.97, 95% CI 0.95–0.99, $P = 4.6 \times 10^{-3}$; Table 2). There was no evidence of heterogeneity by study site among the 25 Caucasian studies ($P = 0.14$; Supplementary Figure 2).

To further understand the association with breast cancer, we restricted the analysis to women with invasive breast cancer. Rs1607237 was associated with a reduced risk of invasive breast cancer (OR = 0.97, 95% CI 0.95–0.99, $P = 0.012$; Table 2), whereas no association with risk of ductal carcinoma *in situ* was observed (OR = 0.93, 95% CI 0.85–1.02, $P = 0.12$). In addition, we explored differences in *PIK3CA* SNP associations in the combined data set by tumour subtype (Supplementary Table 4). The rs1607237 variant was not associated with any subtypes defined by ER, PR or HER2 status, although it is important to note the reduction in sample size when restricting to these tumour subtypes.

DISCUSSION

Here we report an association between inherited variation in the oncogene *PIK3CA* and risk of breast cancer in a large, three-stage analysis utilising nearly 75 000 subjects from 27 case-control study studies. We show that rs1607237 is significantly associated with a small decrease in breast cancer risk (OR = 0.97, 95% CI

0.95–0.99, $P = 9.5 \times 10^{-3}$) in all studies combined and when considering only women of European ancestry in the combined studies (OR = 0.97, 95% CI 0.95–0.99, $P = 4.6 \times 10^{-3}$). However, the association did not achieve significance in the large third stage involving only BCAC studies. Although the first two stages of our analysis suggest an association between *PIK3CA* and breast cancer risk, our inability to confirm this finding in the BCAC studies suggests that the result should be interpreted with caution.

We further explored the linkage disequilibrium patterns in the *PIK3CA* coding and promoter regions to better understand the relationship between rs1607237 and other variation in this region. Rs1607237 was not in strong linkage disequilibrium with two non-synonymous polymorphic variants in the coding region of *PIK3CA*, rs1051399 ($r^2 = 0.0060$) and rs3729680 ($r^2 = 0.034$), which had been genotyped in HapMap samples of European ancestry. However, an additional 18 non-synonymous variants were either not polymorphic or had not been genotyped in the HapMap samples, making inference about the relationship between rs1607237 and all variants of unknown significance in the *PIK3CA* coding region difficult. In addition, two *PIK3CA* promoter SNPs were in low LD with rs1607237 (rs9831234, $r^2 = 0.16$; rs2865084, $r^2 = 0.038$). However, it remains possible that *PIK3CA* promoter SNPs that were not captured in this study are related to breast cancer risk.

It is also important to note that the effect estimate for rs1607237 in the BCAC replication studies and in the overall BCAC, MCBCS and CGEMS studies is quite small (OR = 0.97). This limits our statistical power to detect significant associations in these studies despite the large sample size, particularly in analyses utilising pathology information that is available for only a subset of subjects. Similarly, we had limited power to detect associations in the original MCBCS study with the three non-significant *PIK3CA* SNPs. Thus, it remains possible that evaluation of these variants in the larger BCAC cohort might detect associations with risk. While the effect of rs1607237 on risk is small, the association between inherited variation in this important oncogene and breast cancer risk does provide valuable biological insight into the development of this disease. Validation of rs1607237 in GWAS studies from other large collaborative groups and additional studies by BCAC with detailed pathology information are necessary to confirm this association. Functional evaluation of this variant is needed to fully understand the relationship between inherited *PIK3CA* variation and breast cancer risk.

ACKNOWLEDGEMENTS

The ABCS study was funded by the Dutch Cancer Society (grants NKI 2001-2423; NKI 2007-3839), the Dutch National Genomics

Initiative; ABCS acknowledges all patients, and Sten Cornelissen, Richard van Hien, Flora van Leeuwen, Vincent Smit and other contributors to the 'BOSOM' study (ABCS). The ABCFS, NC-BCFR and OFBCR works were supported by the United States National Cancer Institute, National Institutes of Health (NIH) under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Northern California Cancer Center (U01 CA69417), University of Melbourne (U01 CA69638). Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. JLH is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. MCS is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. BBCC is funded in part by the ELAN fund of the University Hospital Erlangen. The BBS is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The CNIO-BCS was supported by the Genome Spain Foundation, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI081583 and PI081120). We thank Charo Alonso, Tais Moreno, Guillermo Pita, Primitiva Menéndez and Pilar Zamora for their contribution to this work. The GC-HBOC was collected within a project funded by the Deutsche Krebshilfe (Grant number: 107054). It was supported by the Dietmar-Hopp Foundation, the Helmholtz society and the German Cancer Research Center (DKFZ). We thank Sandrine Tchatchou for genotyping. The HABCS was supported by an intramural grant from Hannover Medical School. The HMBCS was supported by short-term fellowships from the German Academic Exchange Program (to NB), and the Friends of Hannover Medical School (to NB). KARBAC acknowledges The Swedish Cancer Society and The Stockholm Cancer Society. KBCP is supported by grants from the Finnish Cancer Society; the Academy of Finland (grant number 127220); the special Government Funding (EVO) of Kuopio University Hospital (grant number 5654113 and 5501) and by

the strategic funding of the University of Eastern Finland. We thank Mrs Helena Kemiläinen, Mrs Aija Parkkinen and Mrs Eija Myöhänen for their skillful technical assistance. We thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001–2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCs was provided by the United States Army Medical Research and Materiel Command (DAMD17-01-1-0729); the Cancer Council of Tasmania and Cancer Foundation of Western Australia; and the NHMRC [199600]. GC-T is supported by the NHMRC. PP is supported by funds from Italian citizens who allocated the 5 × 1000 share of their tax payment to the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects '5 × 1000'). MBCSG thanks Paolo Radice, Bernard Peissel, Daniela Zaffaroni and Marco A Pierotti of the Fondazione IRCCS Istituto Nazionale Tumori and Monica Barile of the Istituto Europeo di Oncologia, Milano, Italy. MCBCS was supported by NIH grant CA122340 and US Recovery act award CA122340Z. Many people have contributed to the MCCS, including the original investigators and the diligent teams who recruited the participants and who continue working on follow-up. Finally, we express our gratitude to the many thousands of Melbourne residents who continue to participate in the study. Cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. OBCS was supported by research grants from the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the Academy of Finland, the University of Oulu and the Oulu University Hospital. SBCS was funded by the Breast Cancer Campaign and Yorkshire Cancer Research. The authors acknowledge Helen Cramp, Sue Higham, Dan Connley, Saba Balasubramanian. The UCIBCS is supported by the National Institutes of Health, National Cancer Institute grants CA-58860, CA-92044 and the Lon V Smith Foundation grant LVS-39420.

Conflict of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (<http://www.nature.com/bjc>)

REFERENCES

- Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. *Breast Cancer Res Treat* **122**(1): 45–53
- Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. *Cancer Biol Ther* **3**(8): 772–775
- Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer Res* **64**(21): 7678–7681
- Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* **296**(5573): 1655–1657
- Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. *Cancer Treat Rev* **30**(2): 193–204
- Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. *Annu Rev Biochem* **67**: 481–507
- Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K, von Smitten K, Blomqvist C, Mannermaa A, Uusitupa M, Eskelinen M, Tengstrom M, Kosma VM, Kataja V, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Devilee P, van

- Asperen CJ, Jacobi CE, Tollenaar RA, Huijts PE, Klijn JG, Chang-Claude J, Kropp S, Slinger T, Flesch-Janys D, Mutschelknauss E, Salazar R, Wang-Gohrke S, Couch F, Goode EL, Olson JE, Vachon C, Fredericksen ZS, Giles GG, Baglietto L, Severi G, Hopper JL, English DR, Southey MC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, Stram DO, Hunter DJ, Hankinson SE, Cox DG, Tamimi R, Kraft P, Sherman ME, Chanock SJ, Lissowska J, Brinton LA, Peplonska B, Hooning MJ, Meijers-Heijboer H, Collee JM, van den Ouweland A, Uitterlinden AG, Liu J, Lin LY, Yuqing L, Humphreys K, Czene K, Cox A, Balasubramanian SP, Cross SS, Reed MW, Blows F, Driver K, Dunning A, Tyrer J, Ponder BA, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gabrieau V, Sigurdson A, Doody M, Struwing JP, Alexander B, Easton DF, Pharoah PD (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet* 4(4): e1000054
- Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME (2009) PIK3CA mutation associates with improved outcome in breast cancer. *Clin Cancer Res* 15(16): 5049–5059
- Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. *Br J Cancer* 94(4): 455–459
- Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. *Ann Surg Oncol* 15(4): 1064–1069
- Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. *Breast Cancer Res Treat* 96(1): 91–95
- Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. *Cell Cycle* 8(9): 1352–1358
- Loi S, Haibe-Kains B, Majaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. *Proc Natl Acad Sci USA* 107(22): 10208–10213
- Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY (2000) PIK3CA as an oncogene in cervical cancer. *Oncogene* 19(23): 2739–2744
- Perez-Tenorio G, Alkhorri L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. *Clin Cancer Res* 13(12): 3577–3584
- Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 65(7): 2554–2559
- Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. *Curr Opin Oncol* 18(1): 77–82
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. *Science* 304(5670): 554
- Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. *Nat Genet* 21(1): 99–102
- Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernardis R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 68(15): 6084–6091
- Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard DS, Fraumeni Jr JF, Hoover RN, Chanock SJ, Hunter DJ (2009) A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet* 41(5): 579–584
- Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W, Rider DN, Vachon CM, Cerhan JR, Olson JE, Couch FJ (2008) Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 17(8): 2101–2108
- Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandrope T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karskens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaboriau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst* 103(3): 250–263

APPENDIX

The GENICA Network

Gene Environment Interaction and Breast Cancer in Germany (GENICA): Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University Tübingen, Germany (Hiltrud Brauch, Christina Justenhoven); Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (UH); Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany (YDK, Christian Baisch); Institute of Pathology, Medical Faculty of the University of Bonn, Germany (Hans-Peter Fischer); Institute for Prevention and Occupational Medicine of

the German Social Accident Insurance (IPA), Bochum, Germany (TB, Beate Pesch, Volker Harth, Sylvia Rabstein). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.

kConFab Investigators, Australian Ovarian Cancer Study Group
Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne VIC 3002, Australia.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.